Article
Strategies to tackle RAS-mutated metastatic colorectal cancer.
ESMO open - 1 Jun 2021
Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patanè D A, Pani A, Scaglione F, Siena S, Sartore-Bianchi A
Abstract excerpt
The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC), conferring poor prognosis and lack of response to anti-epidermal growth factor receptor (EGFR) antibodies. In the last decades, several investigational attempts failed in directly targeting RAS mutations, thus RAS was historically regarded as...
Topics
Join the communities discussing this publication.